LCB has leveraged over forty years of industry learnings to develop proprietary platform technologies (ConjuAll) of conjugation, linker that enable us to design antibody drug conjugates (ADCs) with improved efficacy, safety and tolerability compared to existing ADC drugs. Coupled with LCB’s proprietary payloads, we are assembling a robust pipeline of innovative ADC programs in collaboration with global partners.
Small molecule based drug(NCE)
Our core strength is medicinal chemistry (Legochemistry), a fragment-based drug discovery to accelerate the generation of drug-like molecules. Legochemistry is applied in all our drug discovery efforts in antibiotics, Anti-fibrotic and Immuno-Oncology drugs.